ArticleCureus2025
Efficacy of Ferrous Sulphate in the Management of Iron Deficiency Anemia in Children.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Intermittent oral administration of iron oxide nanoparticles modulates iron homeostasis, hematological, inflammatory, and organ-specific responses in iron-deficient rats.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Iron deficiency anemia (IDA) is a highly prevalent disorder among the pediatric population and has a significant impact on growth and health. Ferrous sulfate is commonly prescribed for the treatment of IDA; however, its efficacy in the pediatric population requires further research. Objective This study aimed to evaluate the efficacy of ferrous sulfate in improving hemoglobin (Hb) and ferritin levels in children diagnosed with IDA. Methods A quasi-experimental study was conducted involving 108 participants aged 1-8 years who were diagnosed with IDA. Participants received ferrous sulfate supplements for three months. Hemoglobin and serum ferritin levels were measured both at baseline and after three months of treatment. Results Ferrous sulfate administration resulted in a significant increase in hemoglobin levels by an average of 3.11 mg/dl and a net increase in ferritin levels by 5.9 ng/ml after 3 months of treatment. Additionally, a positive association was found between low Hb levels and underweight children
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.